Table 3.
Sociodemographic, behavioral and clinical characteristics of mpox participants coinfected with HIV according to hospitalization during mpox follow-up (N = 213).
| Not hospitalized, (N = 189)a | Hospitalized (N = 24)a | Totala (N = 213) | P valueb | |
| Median age (IQR) | 35 (30–40) | 35 (30–42) | 35 (30–40) | 0.75 |
| Age range | 0.83 | |||
| 18–24 years | 11/189 (5.8%) | 1/24 (4.2%) | 12/213 (5.6%) | |
| 25–29 years | 30/189 (15.9%) | 3/24 (12.5%) | 33/213 (15.5%) | |
| 30–39 years | 93/189 (49.2%) | 12/24 (50%) | 105/213 (49.3%) | |
| ≥40 years | 55/189 (29.1%) | 8/24 (33.3%) | 63/213 (29.6%) | |
| Gender identity | >0.99 | |||
| Cisgender men | 180/189 (95.2%) | 24/24 (100%) | 204/213 (95.8%) | |
| Cisgender women | 2/189 (1.1%) | 0/24 | 2/213 (0.9%) | |
| Travesti or TGW | 7/189 (3.7%) | 0/24 | 7/213 (3.3%) | |
| Race | 0.75 | |||
| White | 55/154 (35.7%) | 9/21 (42.9%) | 64/175 (36.6%) | |
| Indigenous | 2/154 (1.3%) | 0/21 | 2/175 (1.1%) | |
| Pardo or mixed | 52/154 (33.8%) | 5/21 (23.8%) | 57/175 (32.6%) | |
| Black | 45/154 (29.2%) | 7/21 (33.3%) | 52/175 (29.7%) | |
| Education | 0.22 | |||
| Primary | 90/156 (57.7%) | 10/24 (41.7%) | 100/180 (55%) | |
| Secondary | 11/156 (7.1%) | 1/24 (4.2%) | 12/180 (7.6%) | |
| Postsecondary | 55/156 (35.3%) | 13/24 (54.2%) | 68/180 (38%) | |
| Reported sexual contact 30 days before symptoms onset | 161/176 (91.5%) | 14/21 (66.7%) | 175/197 (88.8%) | <0.01 |
| Probably vaccinated for smallpox | 15/189 (7.9%) | 4/24 (16.7%) | 19/213 (8.9%) | 0.12 |
| HIV-RNA viral load | 0.04 | |||
| <40 copies/ml | 143/188 (76.1%) | 13/24 (54.2%) | 156/212 (73.6%) | |
| 41–200 copies/ml | 21/188 (11.2%) | 3/24 (12.5%) | 24/212 (11.3%) | |
| 201–1000 copies/ml | 6/188 (3.2%) | 2/24 (8.3%) | 8/212 (3.8%) | |
| >1000 copies/ml | 18/188 (9.5%) | 6/24 (25%) | 24/212 (11.3%) | |
| Median CD4+ (cells/μl, IQR) | 630 (487, 889) | 448 (174, 850) | 624 (463, 889) | 0.02 |
| CD4+ range (cells/μl) | <0.01 | |||
| ≤50 | 1/170 (0.6%) | 4/24 (16.7%) | 5/194 (2.6%) | |
| 51–100 | 0/170 | 1/24 (4.2%) | 1/194 (0.5%) | |
| 101–200 | 2/170 (1.2%) | 3/24 (12.5%) | 5/194 (2.6%) | |
| 201–350 | 11/170 (6.5%) | 2/24 (8.3%) | 13/194 (6.7%) | |
| >350 | 156/170 (91.7%) | 14/24 (58.3%) | 170/194 (87.6%) | |
| ART status | ||||
| Never initiated | 5/187 (2.7%) | 1/24 (4.2%) | 6/211 (2.8%) | 0.02 |
| On ART, regular adherencec | 166/187 (88.8%) | 17/24 (70.8%) | 183/211 (86.8%) | |
| On ART, irregular adherencec | 13/187 (6.9%) | 3/24 (12.5%) | 16/211 (7.6%) | |
| No ART in last 6 monthsc | 3/187 (1.6%) | 3/24 (12.5%) | 6/211 (2.8%) | |
ART, antiretroviral therapy; IQR, interquartile range.
a
n (%); median (IQR).
b
Fisher's exact test; Wilcoxon rank sum test; Pearson's chi-squared test.
c
Self-reported information on ART adherence referring to the 6-month period prior to mpox first assessment. Regular ART adherence was considered if the participant reports taking at least five pills per week in the recall time.